|
|
| 1. |
Preface |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 5-6
Per Venge,
Preview
|
PDF (37KB)
|
|
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00331.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
| 2. |
Allergic inflammation |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 7-12
S. R. Durham,
Preview
|
PDF (562KB)
|
|
摘要:
A greater understanding of the basic mechanisms of allergic inflammation is pertinent to the development of new treatments. Previous studies have focused on the role of mediators of hypersensitivity and effector cells, including mast cells and eosinophils. Recent evidence suggests that IgE‐dependent activation and tissue eosinophilia are under the local regulation of distinct cytokines. Originally described as products from T lymphocytes, these peptide messengers are produced by alternative cells, including mast cells, eosinophils and the respiratory epithelium.In vitrostudies in murine models and using cloned human T lymphocytes indicate the preferential production of “Th2‐type” cytokines, including interleukin‐4 (IL‐4) and IL‐5. This review considers the evidence fromin vivostudies in humans that “Th2‐type” cytokines have a primary role in orchestrating both IgE‐dependent events and local tissue eosinophilia. Novel therapeutic approaches might include a broad strategy directed against T lymphocytes, including the use of immunosuppressive agents or anti CD4 antibodies or more precise targetin
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00332.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
| 3. |
Modulation of human eosinophil chemotaxis and adhesion by anti‐allergic drugsin vitro |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 13-18
R. Sehmi,
G. M. Walsh,
A. Hartnell,
J. Barkans,
J. North,
A. B. Kay,
R. Moqbel,
Preview
|
PDF (497KB)
|
|
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00333.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
| 4. |
The eosinophil granulocyte in allergic inflammation |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 19-24
P. Venge,
Preview
|
PDF (699KB)
|
|
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00334.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
| 5. |
The therapeutic index of antihistamines |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 25-32
M. K. Church,
Preview
|
PDF (881KB)
|
|
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00335.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
| 6. |
The role of food allergy and eosinophils in atopic dermatitis |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 33-37
L. Businco,
P. Meglio,
M. Ferrara,
Preview
|
PDF (526KB)
|
|
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00336.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
| 7. |
Is there a place for antihistamines in the treatment of perennial asthma? |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 38-43
N. ‐l. M. Kjellman,
Preview
|
PDF (817KB)
|
|
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00337.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
| 8. |
Cetirizine in allergic rhinitis |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 44-46
H. B. Kaiser,
Preview
|
PDF (603KB)
|
|
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00338.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
| 9. |
A placebo‐controlled trial of cetirizine in seasonal allergic rhino‐conjunctivitis in children aged 6 to 12 years |
| |
Pediatric Allergy and Immunology,
Volume 4,
Issue S4,
1993,
Page 47-52
M. Masi,
R. Candiani,
H. Venne,
Preview
|
PDF (490KB)
|
|
摘要:
A total of 124 children of both sexes aged between 6 and 12 years with pollen‐associated rhino‐conjunctivitis were included in a multicentre double‐blind study of parallel group design to compare the effects of cetirizine 10 mg daily, given as 5 mg morning and evening for 2 weeks, with those of placebo of identical appearance. Rhinorrhea, sneezing, nasal obstruction and nasal and ocular pruritus were evaluated using symptom scores by patients on daily self‐evaluation cards and by investigators who, in addition, made a global evaluation at the end of treatment. Appropriate wash‐out periods for previous medicines were observed. Unchanged treatment of asthma was allowed and inhaled corticosteroids were continued in 3 placebo patients. Compliance was checked and found to be less than 80% of the prescribed dosage in 2 cetirizine patients. The mean percentage of study days when symptoms were absent or at the most mild (i.e. present but not disturbing), as reported daily by the patients, was significantly greater with cetirizine (56.2%) than placebo (29.7%). This 26.5% difference was considered clinically significant. The value of this method of expressing treatment effects in allergic rhinitis is discussed. Improvement in maximum symptom scores (severest symptoms) assessed by investigators was better for cetirizine than placebo after treatment for 1 week and 2 weeks. Improvement in individual daily symptoms was greater for cetirizine than placebo after a few days. Global evaluations of response by investigators at the end of the study showed improvement in both groups that was significantly greater with cetirizine, providing a response that was considered excellent or good in 79% of patients on cetirizine compared with 50% of patients on placebo. Tolerance was good. Somnolence that was generally mild and transient was reported in 6 patients of the cetirizine group and in 2 patients of the plac
ISSN:0905-6157
DOI:10.1111/j.1399-3038.1993.tb00339.x
出版商:Blackwell Publishing Ltd
年代:1993
数据来源: WILEY
|
|
首页
